Physician profile
Nell L Davis
NPI 1437228780
$7,798.41
in general payments reported to CMS, 2019-2025
49 companies · $26.07 in 2025
The $26.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $1,397 · 2021: $1,331 · 2022: $1,282 · 2023: $1,672 · 2025: $26.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628 · Education: $69.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.46 |
| Education | $69.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.69 | 2021-2023 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $883.13 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $727.75 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $576.27 | 2019-2020 | |
| Lundbeck LLC | $405.04 | 2020-2023 | Rexulti |
| Pfizer INC. | $401.39 | 2019-2023 | |
| Bausch Health US, LLC | $347.07 | 2019-2023 | Aplenzin |
| Lilly USA, LLC | $260.36 | 2019-2023 | Mounjaro |
| Ironshore Pharmaceuticals INC. | $257.82 | 2019 | |
| Merck Sharp & Dohme LLC | $245.47 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $233.12 | 2019-2023 | Rexulti |
| Glaxosmithkline, LLC. | $218.42 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Eisai INC. | $217.00 | 2020-2022 | |
| Astellas Pharma US INC | $194.77 | 2019-2023 | Veozah |
| Tris Pharma INC | $163.59 | 2022-2023 | Dyanavel Xr |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nell Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.